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Aggressive induction chemoimmunotherapy followed by high-dose chemotherapy and autologous stem
cell transplant (ASCT) is a standard option for the initial management of transplant-eligible mantle cell
lymphoma (MCL).1-3 However, the optimal induction regimen before ASCT is unknown. Cytarabine-
based induction achieves excellent response rates and higher rates of minimal residual disease (MRD)
negativity compared with anthracycline-based induction regimens.4-6 While effective, most cytarabine-
based induction regimens require inpatient hospitalization and are associated with significant
hematologic and nonhematologic toxicities.4-6 Rituximab-bendamustine (RB) is a less intensive,
outpatient-based chemoimmunotherapy regimen with excellent long-term efficacy and good tolerability
in transplant-ineligible MCL patients.7-9 However, its role as a pretransplant induction strategy has not
been formerly evaluated.
S1106 is a randomized phase 2 multi-institutional clinical trial comparing induction R-hyper-CVAD
(rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and
methotrexate/cytarabine (RH) with RB followed by ASCT in newly diagnosed MCL patients. We
previously reported that the 2-year progression-free survival (PFS) and overall survival (OS) were similar
with either regimen. However, RH was more toxic than RB, had higher stem cell mobilization failure rates,
and prompted protocol-specified early study closure.10 While premature closure limited the sample size,
we demonstrated for the first time in a prospective setting that outpatient RB treatment can achieve
excellent MRD negativity and could serve as an induction strategy worthy of further study. Given the
increased survival of MCL patients,2 critical assessment of long-term efficacy and toxicity is needed.
Here, we report the 5-year follow-up (FU) of the S1106 study.
Methods
The study design, eligibility criteria, and statistical analyses have been previously published.10
Untreated MCL patients with stage III, IV, or bulky stage II MCL were randomized to 4 cycles of RH
or 6 cycles of RB followed by ASCT. Patients achieving complete response (CR) or partial response
at restaging11 were eligible to proceed to ASCT. A minimum of 1.5 3 106 CD341 cells/kg stem
cells were required to proceed with ASCT. MRD was assessed at baseline and after induction on 12
paired serial samples (2 RH and 10 RB) (Adaptive Biotechnologies). The primary end point of the
trial was 2-year PFS. Secondary end points were overall response rates (ORRs), CR rate, overall
survival (OS), toxicity, and MRD status. To minimize selection bias, a non-preplanned 5-year
landmark analysis was performed from 3 months after registration for the RH arm and from 6 months
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after registration for the RB arm. The 5-year landmark analysis
was used for comparing survival between transplanted and
nontransplanted patients.10
This randomized phase 2 study was conducted by the Southwest
Oncology Group (SWOG) through the National Clinical Trials
Network adult groups (SWOG/Eastern Cooperative Oncology
Group/American College of Radiology Imaging Network alliance)
mechanism. Patients were recruited from 4 January 2012 through
21 June 2013. The study was approved by the institutional review
board at each study site, and written informed consent was
obtained from all patients prior to any study-specific procedures,
per the Declaration of Helsinki. The study was approved and
sponsored by the Cancer Therapy Evaluation Program (https://
clinicaltrials.gov/ct2/show/NCT01412879).
Results and discussion
Among 53 enrolled patients, 52 patients (17 RH and 35 RB) were
evaluable, with 1 patient not starting therapy. Baseline character-
istics were similar, except that more female patients were in the RH
group.10 Median age was 59 and 57 years in the RH and RB arms,
respectively. More than 90% patients on both arms had stage IV
extranodal disease and bone marrow involvement. Approximately
20% of patients had a Ki67 index .30%, and 35% had an
intermediate/high MCL international prognostic index score in each
arm. A total of 9 out of 17 patients (5 patients on protocol and 4 off
protocol) in the RH arm and 23 out of 35 patients (21 patients on
protocol and 2 off protocol) in the RB arm underwent ASCT. The
reasons for discontinuation/stopping before ASCT have been
previously published. Most discontinuations in the RH arm were due
to the inability to collect stem cells (n 5 5) and cytopenias (n 5 6),
whereas in the RB arm, discontinuations were primarily due to
patient choice (n 5 4).10
Updated efficacy results with median FU of 5 years (range,
29 days to 6 years) are detailed in Table 1. Updated ORR and CR
rates were similar in both arms. As previously reported,10 the
2-year PFS was 82% and 81% and the 2-year OS was 88% and
87% in the RH and RB arms, respectively. The 5-year PFS was
62% (95% CI, 34% to 81%) and 66% (95% CI, 45% to 80%) and
the 5-year OS was 74% (95% CI, 44% to 89%) and 80% (95%
CI, 62% to 91%) for RH and RB, respectively (Figure 1). An
updated landmark analysis at the 5-year mark with and without
ASCT in each arm was also performed (Table 1). In the RH arm,
the 5-year landmark PFS estimate was 50% (95% CI, 15% to
77%) vs 73% (95% CI, 28% to 93%) (P 5 .34) and the 5-year
landmark OS was 75% (95% CI, 31% to 93%) vs 73% (95% CI:
28% to 93%) (P 5 .81) for patients undergoing ASCT vs those
who did not. In the RB arm, the 5-year landmark PFS estimates
were 70% (95% CI, 43% to 86%) vs 63% (95% CI, 23% to 86%)
(P 5 .44) and the 5-year landmark OS was 91% (95% CI, 69%
to 98%) vs 60% (95% CI, 20% to 85%) (P 5 .055) for patients
undergoing ASCT vs those who did not.
MRD assessment was performed on 12 paired serial samples (2 RH
and 10 RB). Both paired RH samples were MRD positive at
baseline, and both achieved MRD negativity after induction. In the
RB group, 9 out of 10 samples were MRD positive at baseline, of
which 7 out of 9 (78%) achieved MRD negativity. Three patients
with missing MRD assessment at baseline had negative MRD levels
after induction/before ASCT. The 5-year PFS and OS was 90%
(95% CI, 47% to 99%) for all patients who achieved MRD-negative
status at the end of RB induction.
Of 52 evaluable patients, 10 have died (4 RH and 6 RB), mainly
due to disease progression (n 5 6). Other causes of death
include suicide (n5 1) in the RH arm and typhlitis (n5 1), 1 lung
cancer (n 5 1), and an unknown cause (n 5 1) in the RB
arm. Two patients developed second malignancies. In the RH
arm, 1 patient who did not undergo ASCT was diagnosed with
acute myelogenous leukemia at 5.4 years after diagnosis and
remains alive. In the RB arm, 1 patient who underwent ASCT
developed lung cancer at 2.9 years after diagnosis and
subsequently died.
Long-term results of this study continue to demonstrate excellent
response rates, 5-year PFS, 5-year OS, and MRD negativity with
either RH or RB. However, RH was more toxic and had higher stem
cell mobilization failure rates. RB as induction treatment before
ASCT yielded high response rates, with an ORR of 86% (95%
CI, 70% to 95%) and CR of 43% (95% CI, 26% to 61%), and
demonstrated excellent tolerability as well as durable remissions,
with a 5-year PFS of 66% and 5-year OS of 80%. As previ-
ously published,10 the benefit of ASCT was more pronounced in
the RB arm. The updated 5-year landmark OS estimates continue
to suggest that the ASCT benefit is greater in patients receiving
Table 1. Updated response rates and survival analysis
RH arm (n 5 17) RB arm (n 5 35)
Updated response rates
ORR (95% CI), % 94.1 (71.3-99.9) 85.7 (69.7-95.2)
CR, n (%) 7 (41) 15 (43)
PR, n (%) 9 (53) 15 (43)
Not evaluable, n (%) 1 (6) 5 (14)
ASCT, n (%) 9 (53) 23 (66)
No ASCT, n (%) 8 (47) 12 (34)
Median duration of
response (range), mo
51.3 (8.7-67.4) 50.8 (2.3-64.4)
ASCT 37.3 (8.7-64.4) 51.4 (6.3-64.4)
No ASCT 52.5 (43.4-67.4) 31.2 (2.3-55.3)
Landmark analysis
5-y PFS ASCT vs no ASCT
(95% CI), %
50 (15-77) vs 73 (28-93)
(P 5 .34)
70 (43-86) vs 63% (23-86)
(P 5 .44)
5-y OS ASCT vs No ASCT
(95% CI), %
75 (31-93) vs 73 (28-93)
(P 5 .81)




2 y 82 (53-94) 81 (63-91)
5 y 62 (34-81) 66 (45-80)
OS
2 y 88 (59-97) 87 (70-95)
5 y 74 (44-89) 80 (62-91)
The best clinical response was determined by investigators according to the Revised
Response Criteria for Malignant Lymphoma.11
CI, confidence interval; PR, partial response.
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induction RB, although the limited sample size precludes definitive
conclusions.
Although the optimal induction regimen is unknown, cytarabine-
based induction has been favored, including the Nordic regimen,
LyMa protocol and the European MCL regimens. In randomized
settings, the reason for improved outcomes with cytarabine-based
regimens may be the higher likelihood of achieving MRD
negativity.12 However, this comes with increased cytopenias
and frequent inpatient delivery of therapy. In our trial, the RH
arm had significantly more grade 3/4 neutropenia, anemia, thrombo-
cytopenia, and febrile neutropenia and is consistent with rates
reported with the Nordic and European MCL Network regimens. The
updated analysis of our study demonstrated that RB induction
achieved a 5-year PFS of 66% and OS of 80% with MRD-negativity
rates of 78%. These results are provocatively similar to intensive
cytarabine-based induction therapy,4-6,12,13 albeit with decreased
hematologic toxicity and outpatient treatment.
In conclusion, with 5 years of FU, S1106 shows excellent
survival, with.70% patients alive and 60% patients disease-free
in both arms. The comparison with RH is underpowered due to
early closure of this arm. Patients receiving RB induction had
excellent 5-year PFS, OS, and MRD-negativity rates. Overall,
S1106 demonstrated that an outpatient-based, less intensive
induction therapy of bendamustine plus rituximab is highly
effective, safe, and durable in untreated transplant-eligible
MCL patients. Our results have informed the design of a future
Eastern Cooperative Oncology Group–led trial (EA4181) wherein
a bendamustine-based induction chemotherapy backbone is
being tested with cytarabine and/or a BTK-inhibitor in untreated
MCL patients.
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Figure 1. Five-year PFS and OS. Five-year Kaplan-Meier PFS (A) and OS (B) curves. R, rituximab; R-HCVAD/MTX/Ara-C, rituximab plus hyperfractionated cyclophospha-
mide, vincristine, doxorubicin, and dexamethasone) and methotrexate/cytarabine.
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